Is the FDA overestimating the risks of the Johnson & Johnson COVID-19 vaccine?

Johnson & Johnson COVID-19 vaccine.
(Image credit: Matthew Hatcher/Getty Images)

No one knows for sure yet whether the FDA made the right call in pausing the usage of the Johnson & Johnson COVID-19 vaccine, but the agency is already facing criticism for poor risk assessment and shortsightedness. Some state officials are worried the decision will increase vaccine hesitancy, regardless of which shot people are set to receive. "There's nothing we can do to restore confidence," one GOP state official told CBS News.

Nearly 7 million doses of the single-shot vaccine have been administered in the United States, and there are six reported cases of recipients developing a rare and severe type of blood clot. Dr. Megan Ranney, an emergency room physician and professor at Brown University, tweeted on Tuesday that a connection is "plausible," but even if it turns out to be real, she added, the risk is still far lower than the risk of developing a blood clot from a COVID-19 infection, which may be as high as 20 percent.

Subscribe to The Week

Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

SUBSCRIBE & SAVE
https://cdn.mos.cms.futurecdn.net/flexiimages/jacafc5zvs1692883516.jpg

Sign up for The Week's Free Newsletters

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

Sign up
Explore More
Tim O'Donnell

Tim is a staff writer at The Week and has contributed to Bedford and Bowery and The New York Transatlantic. He is a graduate of Occidental College and NYU's journalism school. Tim enjoys writing about baseball, Europe, and extinct megafauna. He lives in New York City.